Anavex Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>AL</div>
AVXL -- USA Stock  

USD 6.03  0.06  0.99%

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to summarize Anavex Life Sciences against current market trends. As we have suggested previously, Anavex Life is beginning its pull down as stakeholders shift to be more bearish due to the increased sector volatility. Anavex Life Sciences moves completely opposite to the market. A great deal of the latest Anavex Life price action was an exact opposite of how the market twisted in the last few months. Steady technical and fundamental indicators of the company may denote signs of medium-term price drift for stakeholders. Anavex Life Sciences is scheduled to announce its earnings today. The next earnings report is expected on the 4th of February 2021.
Published over three weeks ago
View all stories for Anavex Life | View All Stories
Our new technical analysis of Anavex Life Sciences (NASDAQ:AVXL)
This firm's average rating is Strong Buy from 4 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Anavex Life market sentiment investors' perception of the future value of Anavex. Let us look at a few aspects of Anavex technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Anavex Life Sciences. In general, we focus on analyzing Anavex Life stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Anavex Life's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Anavex Life's intrinsic value. In addition to deriving basic predictive indicators for Anavex Life, we also check how macroeconomic factors affect Anavex Life price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Anavex Life's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Anavex Life in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Anavex Life. Your research has to be compared to or analyzed against Anavex Life's peers to derive any actionable benefits. When done correctly, Anavex Life's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Anavex Life Sciences.

How does Anavex Stands against Peers?

Analyzing Anavex Life competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Anavex Life across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Anavex Life Competition Details

How Anavex utilizes its cash?

To perform a cash flow analysis of Anavex Life, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Anavex Life is receiving and how much cash it distributes out in a given period. The Anavex Life cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Anavex Life Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (19.66 Million)

Closer look at Anavex Life Downside Variance

Anavex Life Sciences has current Downside Variance of 48.24. Downside Variance (or DV) is measured by target semi-variance and is termed downside volatility. It is expressed in percentages and therefore allows for rankings in the same way as variance. One way to view downside volatility is the annualized variance of returns below the target.

Downside Variance is the probability-weighted squared below-target returns. The squaring of the below-target returns has the effect of penalizing failures at an exponential rate. This is consistent with observations made on the behavior of individual decision-making under.

Downside Variance 
 = 
SUM(RET DEV)2 
N(ER) 
 = 
48.24
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N(ER) = Number of points with returns less than expected return for the period
Let's now compare Anavex Life Downside Variance to its closest peers:
AVXL
NK
DMAC
DNLI
DRNA
AVXL48.24079768470137
NK28.9
DMAC11.32
DNLI9.57
DRNA6.43

Our take on Anavex Life small pull down

The semi deviation is down to 6.32 as of today. Anavex Life Sciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Anavex Life Sciences independently to ensure intended market timing strategies are aligned with expectations about Anavex Life volatility.

The Bottom Line

While some other entities in the biotechnology industry are either recovering or due for a correction, Anavex may not be as strong as the others in terms of longer-term growth potentials. In closing, as of the 28th of December 2020, our primary 30 days advice on the company is Cautious Hold. We believe Anavex Life is currently undervalued with very high probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Anavex Life Sciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com